EBIO Eleven Biotherapeutics, Inc. gains 23% Sep 27, 2017

Eleven Biotherapeutics, Inc., a biologic oncology company, focuses on the development of novel therapies based upon tumor targeting antibody fragments genetically fused to a cytotoxic protein payload called Targeted Protein Therapeutics (TPTs). The company's advanced TPTs are in clinical development for cancers, which have significant unmet needs for patients. It is developing Vicinium that is in active Phase 3 clinical trial in the United States and Canada for the treatment of non-muscle invasive bladder cancer; and Proxinium for late stage squamous cell carcinoma of the head and neck, preparing for a Phase 2 clinical trial in combination with cancer immunotherapy. The company was founded in 2008 and is based in Cambridge, Massachusetts. http://www.priceseries.com/trade/EBIO-Eleven-Biotherapeutics-Inc-stock-gains-23-percent-a-Trade-Record-by-priceSeries-2017090720170927.html